Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
20.00
+0.16 (0.81%)
At close: Aug 6, 2026, 4:00 PM EDT
19.85
-0.15 (-0.75%)
Pre-market: Aug 7, 2026, 4:01 AM EDT
Xencor Employees
Xencor had 260 employees as of December 31, 2025. The number of employees increased by 10 or 4.00% compared to the previous year.
Employees
260
Change (1Y)
10
Growth (1Y)
4.00%
Revenue / Employee
$403,742
Profits / Employee
-$628,173
Market Cap
1.49B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 260 | 10 | 4.00% | 260 | 0 |
| Dec 31, 2024 | 250 | -30 | -10.71% | 250 | 0 |
| Dec 31, 2023 | 280 | -1 | -0.36% | 280 | 0 |
| Dec 31, 2022 | 281 | 27 | 10.63% | 281 | 0 |
| Dec 31, 2021 | 254 | 52 | 25.74% | 254 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Intellia Therapeutics | 377 |
| Vir Biotechnology | 367 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
| Absci | 140 |
| MoonLake Immunotherapeutics | 130 |
| ORIC Pharmaceuticals | 104 |
| ArriVent BioPharma | 77 |
XNCR News
- 20 hours ago - Xencor price target raised to $30 from $26 at Wedbush - TheFly
- 21 hours ago - Xencor price target raised to $44 from $43 at Cantor Fitzgerald - TheFly
- 22 hours ago - Xencor price target raised to $20 from $19 at RBC Capital - TheFly
- 1 day ago - Xencor reports Q2 EPS (29c), consensus (84c) - TheFly
- 1 day ago - Xencor Reports Second Quarter 2026 Financial Results - Business Wire
- 1 day ago - Xencor Earnings release: Q2 2026 - Filings
- 1 day ago - Xencor Quarterly report: Q2 2026 - Filings
- 3 days ago - Xencor participates in a conference call with Cantor - TheFly